Botulinum toxin type a for chronic migraine

Current Neurology and Neuroscience Reports

Volumn 10, Issue 2, 2010, Pages 140-146

  Ashkenazi, Avi ^a  

^a Neurologic Group of Bucks/Montgomery County   (United States)

Author keywords

Botulinum toxin; Chronic migraine

Indexed keywords

BOTULINUM TOXIN A;

ALLODYNIA; ANALGESIC ACTIVITY; CENTRAL NERVOUS SYSTEM FUNCTION; CLINICAL TRIAL; DIABETIC NEUROPATHY; DISEASE DURATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; MUSCLE ATROPHY; MUSCLE SPINDLE AFFERENT NERVE; NEUROPATHIC PAIN; NONHUMAN; QUALITY OF LIFE; REVIEW; TRANSFORMED MIGRAINE;

BOTULINUM TOXIN TYPE A; CHRONIC DISEASE; HUMANS; MIGRAINE DISORDERS; NEUROMUSCULAR AGENTS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 77953545480     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-010-0087-5     Document Type: Review

References (35)

1. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24(Suppl 1):9-160.
2. Bigal ME, Lipton RB, Tepper SJ, et al.: Primary chronic daily headache and its subtypes in adolescents and adults. Neurology 2004, 63:843-847.
3. Dodick DW: Clinical practice. Chronic daily headache. N Engl J Med 2006, 354:158-165.
4. Scher AI, Stewart WF, Ricci JA, Lipton RB: Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003, 106:81-89.
5. Silberstein SD, Goadsby PJ: Migraine: Preventive treatment. Cephalalgia 2002, 22:491-512.
6. Ashkenazi A, Levin M, Dodick DW: Peripheral procedures: Nerve blocks, peripheral neurostimulation and botulinum neurotoxin injections. In Wolff's Headache and Other Head Pain. Edited by Silberstein SD, Lipton RB, Dodick DW. New York: Oxford University Press; 2007:767-792.
7. Turton K, Chaddock JA, Acharya KR: Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility. Trends Biochem Sci 2002, 27:552-558.
8. Brin MF: Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 1997, 6:S146-S168.
9. Binder WJ, Brin MF, Blitzer A, et al.: Botulinum toxin type A (Botox) for treatment of migraine headaches: An open-label study. Otolaryngol Head Neck Surg 2000, 123:669-676.
10. Ashkenazi A, Silberstein SD: Botulinum toxin and other new approaches to migraine therapy. Annu Rev Med 2004, 55:505-518.
11. Welch MJ, Purkiss JR, Foster KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000, 38:245-258.
12. McMahon HT, Foran P, Dolly JO, et al.: Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gammaaminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. J Biol Chem 1992, 267:21338-21343.
13. Durham PL, Cady R, Cady R: Regulation of calcitonin generelated peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache 2004, 44:35-42.
14. Cui M, Khanijou S, Rubino J, Aoki KR: Subcutaneous administration of botulinum toxin A reduces formalininduced pain. Pain 2004, 107:125-133.
15. Oshinsky ML: Botulinum toxins and migraine: How does it work. Practical Neurol 2004, 4:S10-S13.
16. Antonucci F, Rossi C, Gianfranceschi L, et al.: Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 2008, 28:3689-3696. This very interesting study showed a transfer of active BoNT-A through axonal transport and transcytosis to sensory synapses.
17. Filippi GM, Errico P, Santarelli R, et al.: Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993, 113:400-404.
18. Rosales RL, Arimura K, Takenaga S, Osame M: Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996, 19:488-496.
19. Ranoux D, Attal N, Morain F, Bouhassira D: Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008, 64:274-283. This important, welldesigned study showed an analgesic effect of BoNT-A in patients with neuropathic pain.
20. Yuan RY, Sheu JJ, Yu JM, et al.: Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial. Neurology 2009, 72:1473-1478. This is another well-designed study that showed efficacy of BoNT-A in treating painful diabetic neuropathy.
21. Mathew NT, Frishberg BM, Gawel M, et al.: Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebocontrolled trial. Headache 2005, 45:293-307.
22. Dodick DW, Mauskop A, Elkind AH, et al.: Botulinum toxin type A for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebo-controlled study. Headache 2005, 45:315-324.
23. Ondo WG, Vuong KD, Derman HS: Botulinum toxin A for chronic daily headache: A randomized, placebo-controlled, parallel design study Cephalalgia 2004, 24:60-65.
24. Silberstein SD, Stark SR, Lucas SM, et al.: Botulinum toxin type A for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005, 80:1126-1137.
25. Freitag FG, Diamond S, Diamond M, Urban G: Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 2008, 48:201-209.
26. Aurora SK, Schim JD, Cutrer FM, et al.: Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 1 trial double-blind phase [abstract]. Cephalalgia 2009, 29:S29.
27. Dodick DW, Smith TR, Becker WJ, et al.: Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 2 trial double-blind phase [abstract]. Cephalalgia 2009, 29:S29.
28. Jakubowski M, McAllister PJ, Bajwa ZH, et al.: Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A. Pain 2006, 125:286-295.
29. Mathew NT, Kailasam J, Meadors L: Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 2008, 48:194-200.
30. Eross EJ, Gladstone JP, Lewis S, et al.: Duration of migraine is a predictor for response to botulinum toxin type A. Headache 2005, 45:308-314.
31. Mathew NT, Reuveni U, Perez F: Transformed or evolutive migraine. Headache 1987, 27:102-106.
32. Tepper SJ, Bigal ME, Sheftell FD, Rapoport AM: Botulinum neurotoxin type A in the preventive treatment of refractory headache: A review of 100 consecutive cases. Headache 2004, 44:794-800.
33. Bendtsen L, Mattsson P, Zwart JA, Lipton RB: Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia 2003, 23:487-490.
34. Loder E, Goldstein R, Biondi D: Placebo effects in oral triptan trials: The scientific and ethical rationale for continued use of placebo controls. Cephalalgia 2005, 25:124-131.
35. Schwedt TJ, Hentz JG, Dodick DW: Factors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum toxin for migraine. Cephalalgia 2007, 27:528-534.